Overactive bladder (OAB), the most prevalent form of urinary incontinence, is due to involuntary contractions of the bladder (detrusor) muscle with symptoms of urinary frequency, urgency, and urge incontinence. Overactive bladder is often managed with pharmacologic intervention that focuses on inhibiting detrusor activity and increasing bladder capacity.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.